The use erythrocyte glutathione as a predictive marker for malignant melanoma

A. Moral, M. J. Lafuente, A. Lafuente, T. Castel, A. M. Balesta, M. Lecha, M. Trias, T. Castel, J. M. Mascaro, J. Castro, S. Puig, J. Malvehy, J. Soler, E. Yachi, J. Piulachs, C. Barruiso, A. Vilalta, E. Martin, B. Mellado, D. Colomer & 13 others J. Estape, L. Gonzalez, Xavier P. Estivill, A. Ruiz, M. Mila, A. Lafuente, M. J. Lafuente, X. Casterad, N. Laso, R. Molina, R. Vilella, J. Mila, J. Vidal

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Glutathione (GSH) may provide defense against reactive oxygen species (ROS) generated by ultraviolet radiation. Furthermore, some authors have demonstrated a relationship between the GSH of peripheral blood erythrocytes (GSHe) and resistance to chemotherapy. Patients & Methods. To observe the influence of GSH on the genesis and evolution of Malignant Melanoma (MM), we assessed the concentration of GSH in erythrocytes (GSHe) in MM patients (n=566) and controls (n=164) by the method of Beutler (1963). Results: No differences were found between the two groups (5.94±1.61 cases vs 6.08±1.49 mmol/gr Hb, controls; p>0.05). Fifty seven patients with poor evolution (disease-free survival < 2years) had higher GSH levels than the remaining patients (6.35±1.83 vs 5.83±1.62 mmol/g Hb; p<0.01). GSHe increased significantly after antineoplastic therapy (4.75±1.26 vs 7.73±1.39 mmoVg Hb; p<0.001), thus indicating a possible role in chemoresistance. 2 Conclusions: GSHe is not related to the risk of developing MM. GSHe may be related to the evolution of MM, being higher in patients who suffer relapse or metastasis. GSHe increases significantly during cytostatic treatment.

Original languageEnglish
Pages (from-to)4757-4760
Number of pages4
JournalAnticancer Research
Volume20
Issue number6 C
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Glutathione
Melanoma
Erythrocytes
Cytostatic Agents
Antineoplastic Agents
Disease-Free Survival
Reactive Oxygen Species
Radiation
Neoplasm Metastasis
Recurrence
Drug Therapy
Therapeutics

Keywords

  • Glutathione
  • Malignant melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Moral, A., Lafuente, M. J., Lafuente, A., Castel, T., Balesta, A. M., Lecha, M., ... Vidal, J. (2000). The use erythrocyte glutathione as a predictive marker for malignant melanoma. Anticancer Research, 20(6 C), 4757-4760.

The use erythrocyte glutathione as a predictive marker for malignant melanoma. / Moral, A.; Lafuente, M. J.; Lafuente, A.; Castel, T.; Balesta, A. M.; Lecha, M.; Trias, M.; Castel, T.; Mascaro, J. M.; Castro, J.; Puig, S.; Malvehy, J.; Soler, J.; Yachi, E.; Piulachs, J.; Barruiso, C.; Vilalta, A.; Martin, E.; Mellado, B.; Colomer, D.; Estape, J.; Gonzalez, L.; Estivill, Xavier P.; Ruiz, A.; Mila, M.; Lafuente, A.; Lafuente, M. J.; Casterad, X.; Laso, N.; Molina, R.; Vilella, R.; Mila, J.; Vidal, J.

In: Anticancer Research, Vol. 20, No. 6 C, 2000, p. 4757-4760.

Research output: Contribution to journalArticle

Moral, A, Lafuente, MJ, Lafuente, A, Castel, T, Balesta, AM, Lecha, M, Trias, M, Castel, T, Mascaro, JM, Castro, J, Puig, S, Malvehy, J, Soler, J, Yachi, E, Piulachs, J, Barruiso, C, Vilalta, A, Martin, E, Mellado, B, Colomer, D, Estape, J, Gonzalez, L, Estivill, XP, Ruiz, A, Mila, M, Lafuente, A, Lafuente, MJ, Casterad, X, Laso, N, Molina, R, Vilella, R, Mila, J & Vidal, J 2000, 'The use erythrocyte glutathione as a predictive marker for malignant melanoma', Anticancer Research, vol. 20, no. 6 C, pp. 4757-4760.
Moral A, Lafuente MJ, Lafuente A, Castel T, Balesta AM, Lecha M et al. The use erythrocyte glutathione as a predictive marker for malignant melanoma. Anticancer Research. 2000;20(6 C):4757-4760.
Moral, A. ; Lafuente, M. J. ; Lafuente, A. ; Castel, T. ; Balesta, A. M. ; Lecha, M. ; Trias, M. ; Castel, T. ; Mascaro, J. M. ; Castro, J. ; Puig, S. ; Malvehy, J. ; Soler, J. ; Yachi, E. ; Piulachs, J. ; Barruiso, C. ; Vilalta, A. ; Martin, E. ; Mellado, B. ; Colomer, D. ; Estape, J. ; Gonzalez, L. ; Estivill, Xavier P. ; Ruiz, A. ; Mila, M. ; Lafuente, A. ; Lafuente, M. J. ; Casterad, X. ; Laso, N. ; Molina, R. ; Vilella, R. ; Mila, J. ; Vidal, J. / The use erythrocyte glutathione as a predictive marker for malignant melanoma. In: Anticancer Research. 2000 ; Vol. 20, No. 6 C. pp. 4757-4760.
@article{43f29d7a35c1471f859ff99430fd0ca2,
title = "The use erythrocyte glutathione as a predictive marker for malignant melanoma",
abstract = "Background: Glutathione (GSH) may provide defense against reactive oxygen species (ROS) generated by ultraviolet radiation. Furthermore, some authors have demonstrated a relationship between the GSH of peripheral blood erythrocytes (GSHe) and resistance to chemotherapy. Patients & Methods. To observe the influence of GSH on the genesis and evolution of Malignant Melanoma (MM), we assessed the concentration of GSH in erythrocytes (GSHe) in MM patients (n=566) and controls (n=164) by the method of Beutler (1963). Results: No differences were found between the two groups (5.94±1.61 cases vs 6.08±1.49 mmol/gr Hb, controls; p>0.05). Fifty seven patients with poor evolution (disease-free survival < 2years) had higher GSH levels than the remaining patients (6.35±1.83 vs 5.83±1.62 mmol/g Hb; p<0.01). GSHe increased significantly after antineoplastic therapy (4.75±1.26 vs 7.73±1.39 mmoVg Hb; p<0.001), thus indicating a possible role in chemoresistance. 2 Conclusions: GSHe is not related to the risk of developing MM. GSHe may be related to the evolution of MM, being higher in patients who suffer relapse or metastasis. GSHe increases significantly during cytostatic treatment.",
keywords = "Glutathione, Malignant melanoma",
author = "A. Moral and Lafuente, {M. J.} and A. Lafuente and T. Castel and Balesta, {A. M.} and M. Lecha and M. Trias and T. Castel and Mascaro, {J. M.} and J. Castro and S. Puig and J. Malvehy and J. Soler and E. Yachi and J. Piulachs and C. Barruiso and A. Vilalta and E. Martin and B. Mellado and D. Colomer and J. Estape and L. Gonzalez and Estivill, {Xavier P.} and A. Ruiz and M. Mila and A. Lafuente and Lafuente, {M. J.} and X. Casterad and N. Laso and R. Molina and R. Vilella and J. Mila and J. Vidal",
year = "2000",
language = "English",
volume = "20",
pages = "4757--4760",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 C",

}

TY - JOUR

T1 - The use erythrocyte glutathione as a predictive marker for malignant melanoma

AU - Moral, A.

AU - Lafuente, M. J.

AU - Lafuente, A.

AU - Castel, T.

AU - Balesta, A. M.

AU - Lecha, M.

AU - Trias, M.

AU - Castel, T.

AU - Mascaro, J. M.

AU - Castro, J.

AU - Puig, S.

AU - Malvehy, J.

AU - Soler, J.

AU - Yachi, E.

AU - Piulachs, J.

AU - Barruiso, C.

AU - Vilalta, A.

AU - Martin, E.

AU - Mellado, B.

AU - Colomer, D.

AU - Estape, J.

AU - Gonzalez, L.

AU - Estivill, Xavier P.

AU - Ruiz, A.

AU - Mila, M.

AU - Lafuente, A.

AU - Lafuente, M. J.

AU - Casterad, X.

AU - Laso, N.

AU - Molina, R.

AU - Vilella, R.

AU - Mila, J.

AU - Vidal, J.

PY - 2000

Y1 - 2000

N2 - Background: Glutathione (GSH) may provide defense against reactive oxygen species (ROS) generated by ultraviolet radiation. Furthermore, some authors have demonstrated a relationship between the GSH of peripheral blood erythrocytes (GSHe) and resistance to chemotherapy. Patients & Methods. To observe the influence of GSH on the genesis and evolution of Malignant Melanoma (MM), we assessed the concentration of GSH in erythrocytes (GSHe) in MM patients (n=566) and controls (n=164) by the method of Beutler (1963). Results: No differences were found between the two groups (5.94±1.61 cases vs 6.08±1.49 mmol/gr Hb, controls; p>0.05). Fifty seven patients with poor evolution (disease-free survival < 2years) had higher GSH levels than the remaining patients (6.35±1.83 vs 5.83±1.62 mmol/g Hb; p<0.01). GSHe increased significantly after antineoplastic therapy (4.75±1.26 vs 7.73±1.39 mmoVg Hb; p<0.001), thus indicating a possible role in chemoresistance. 2 Conclusions: GSHe is not related to the risk of developing MM. GSHe may be related to the evolution of MM, being higher in patients who suffer relapse or metastasis. GSHe increases significantly during cytostatic treatment.

AB - Background: Glutathione (GSH) may provide defense against reactive oxygen species (ROS) generated by ultraviolet radiation. Furthermore, some authors have demonstrated a relationship between the GSH of peripheral blood erythrocytes (GSHe) and resistance to chemotherapy. Patients & Methods. To observe the influence of GSH on the genesis and evolution of Malignant Melanoma (MM), we assessed the concentration of GSH in erythrocytes (GSHe) in MM patients (n=566) and controls (n=164) by the method of Beutler (1963). Results: No differences were found between the two groups (5.94±1.61 cases vs 6.08±1.49 mmol/gr Hb, controls; p>0.05). Fifty seven patients with poor evolution (disease-free survival < 2years) had higher GSH levels than the remaining patients (6.35±1.83 vs 5.83±1.62 mmol/g Hb; p<0.01). GSHe increased significantly after antineoplastic therapy (4.75±1.26 vs 7.73±1.39 mmoVg Hb; p<0.001), thus indicating a possible role in chemoresistance. 2 Conclusions: GSHe is not related to the risk of developing MM. GSHe may be related to the evolution of MM, being higher in patients who suffer relapse or metastasis. GSHe increases significantly during cytostatic treatment.

KW - Glutathione

KW - Malignant melanoma

UR - http://www.scopus.com/inward/record.url?scp=0034495690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034495690&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 4757

EP - 4760

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 C

ER -